BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 23, 2017
View Archived Issues
Atara Biotherapeutics starts phase I study of allogeneic ATA-188 in multiple sclerosis
Read More
[68Ga]NODAGA-exendin-4 used to image beta cells after Roux-en-Y gastric bypass
Read More
Novel orally bioavailable BAX activator shows promising antitumor activity in leukemia xenografts
Read More
Novel glucosylceramidase activators presented by Lysosomal Therapeutics
Read More
Osimertinib-savolitinib combination shows promise in EGFR-mutant NSCLC
Read More
Researchers describe a novel athyroid mouse model
Read More
FDA approves Shingrix
Read More
Spero Therapeutics commences clinical testing of SPR-994
Read More
FDA approves Simponi Aria for psoriatic arthritis and ankylosing spondylitis
Read More
FDA grants new breakthrough therapy designation to Tafinlar + Mekinist in melanoma
Read More
VBL Therapeutics' VB-111 granted orphan medicinal product status in E.U.
Read More
FDA grants orphan drug designation to Cx-601 for fistulizing Crohn's disease
Read More
Activity seen with etirinotecan pegol in phase II small-cell lung cancer trial
Read More
New susceptibility genes revealed for Kawasaki disease
Read More
FDA issues complete response letter for Xyosted
Read More
FDA approves Bydureon BCise
Read More
Ergomed reports phase II topline results for first-in-class hemostat PeproStat
Read More
Japanese NDA filing for Lynparza for germline BRCA-mutated, HER2-negative metastatic breast cancer
Read More
Population Council initiates phase I study of griffithsin gel for HIV prevention
Read More
Immunomedics initiates phase III study of sacituzumab govitecan for triple-negative breast cancer
Read More
